Modernatx, Inc.

Eric Yi-Chun Huang

Giuseppe Ciaramella

Sunny Himansu

Sayda Mahgoub Elbashir

Stephen G Hoge

Tirtha Chakraborty

Stephane Bancel

Jeff Lynn Ellsworth

Justin Guild

Lan Zhang

Antonin De Fougerolles

Joseph Beene Bolen

Tal Zaks

Axel Bouchon

Kapil Bahl

Kerim Babaoglu

Nicholas M Valiante

David C Nickle

Sushma Gurumurthy

Tai Zaks

Jessica Anne Flynn

Nicholas Valiante

Sze-Wah Tse

Jared Iacovelli

Kristine McKinney

Christina Henderson

Stephen Michael Kelsey

Kahlin Cheung-ong

Josh Frederick

Michael Morin

The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.

Nucleic acid vaccines

The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.

Concatemeric peptide epitope RNAs

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of long-lived polynucleotides, primary transcripts and mmRNA molecules.

Long-lived polynucleotide molecules

The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.

Broad spectrum influenza virus vaccine

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.

CHIKV RNA vaccines

The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.

Zika virus RNA vaccines

Chikungunya virus RNA vaccines

The present invention relates to compositions comprising and methods of using synthetic polynucleotides, e.g., modified mRNA, encoding CRISPR related proteins including dCAS9 and synthetic sgRNAs targeting a gene of interest.

Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use

Infectious disease vaccines

The disclosure features immunomodulatory therapeutic compositions of an mRNA encoding an activating oncogene mutation peptide and an mRNA encoding a polypeptide that enhances immune responses to the activating oncogene mutation peptide, for example an mRNA encoding an immune potentiator. The disclosure also features methods of using the same, for example, to stimulate anti-cancer immune responses.

Immunomodulatory therapeutic MRNA compositions encoding activating oncogene mutation peptides

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.

The disclosure relates to Zika virus infection and the treatment thereof. The invention includes ribonucleic acid compositions, as well as methods of using the compositions for treating and preventing Zika virus infection.

Growing community of inventors

Boston, MA, United States of America

Eric Yi-Chun Huang